Day: May 15, 2019

Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer

abiraterone-approved-for-earlier-use-in-men-with-metastatic-prostate-cancer

February 15, 2018, by NCI Staff FDA has approved abiraterone (Zytiga®), in combination with androgen-deprivation therapy (ADT), to treat hormone-sensitive metastatic prostate cancer. Credit: Adapted from Front Oncol. Dec. 2013. doi: 10.3389/fonc.2013.00293. Creative Commons 3.0. Even more men with advanced prostate cancer may benefit from the drug abiraterone (Zytiga®), after […]